Synlogic is a clinical-stage biotechnology company developing a new class of biotherapeutics through its proprietary approach to synthetic biology. Synlogic’s pipeline includes its lead program in phenylketonuria (PKU) and additional novel drug candidates designed to treat homocystinuria (HCU), enteric hyperoxaluria (EH), and gout. The rapid advancement of these potential biotherapeutics, called Synthetic Biotics, has been enabled by Synlogic’s proprietary, reproducible, target-specific drug design. Synlogic uses programmable, precision genetic engineering of well-characterized probiotics to exert localized activity for therapeutic benefit, with a focus on metabolic and immunologic diseases. Synlogic also has research collaborations established with Roche and Ginkgo Bioworks.